Rheumatology
| Osteoarthritis and Related Disorders
Rheumatology
Osteoarthritis and Related Disorders

Observed efficacy with subcutaneous tanezumab is early and maintained in patients with osteoarthritis: results from a 56-week randomized NSAID-controlled study

book_2 Source: ACR Convergence 2020 - Poster session - Abs #1642
calendar_today Published on Medfyle: November 2020
headphones 2 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • This was a phase  3, randomized, double-blind, double-dummy, NSAID-controlled, parallel-group study in patients with moderate-to-severe hip or knee osteoarthritis.
  • Patients receiving tanezumab or NSAID experienced improvements in pain and function within the first few weeks that was maintained throughout the treatment period.
  • Tanezumab versus NSAID had similar or greater improvement in pain and function scores at all timepoints during the treatment period.
  • The magnitude of change from baseline in pain and function scores observed with tanezumab was largely comparable to those observed in recent 16- and 24-week placebo-controlled studies of tanezumab.
Presenting Author
Read more arrow_downward Hide arrow_upward

Tuhina Neogi, MD, PhD, FRCPC
Professor of Medicine
Boston University School of Medicine
Boston, MA

Dr. Tuhina Neogi is a Professor of Medicine and of Public Health at Boston University Schools of Medicine (BUSM) and of Public Health (BUSPH), and is Chief of Rheumatology at BUSM/Boston Medical Center. Dr. Neogi completed her medical degree and clinical training at the University of Toronto, and obtained her PhD in Epidemiology at BUSPH.

As a rheumatologist and epidemiologist, her research has focused on osteoarthritis and gout, pain mechanisms in osteoarthritis, and methodologic issues of relevance for rheumatic diseases. She has had continuous peer-reviewed funding since 2003, and have over 250 peer-reviewed publications to date. She is a past chair of the FDA Arthritis Advisory Committee, serves or has served on the board of international societies (Crystal-Associated Diseases Network (G-CAN), Osteoarthritis Research Society International (OARSI)), and on committees for the American College of Rheumatology (ACR) and International Association for the Study Pain (IASP), among others. Her work was recognized with the 2014 ACR Henry Kunkel Young Investigator Award for outstanding and promising independent contributions to rheumatology research. She has led or engaged in development of new classification criteria for a number of rheumatic diseases, and has led ACR treatment guidelines for gout and osteoarthritis.

In addition to research, clinical work, and teaching, one of her key roles is to mentor trainees and junior faculty in musculoskeletal disease-related research. She developed a CTSI Research Career Support Program initiative, PRIME (Pathways to Research Independence and Mentoring Excellence), which aims to support early career mentored researchers to successfully transition to becoming independent researchers. Numerous mentees have received career development awards, including NIH K awards. In recognition for her mentoring excellence, she was awarded the 2016 Robert Dawson Evans Research Mentoring Award. In addition, Dr. Neogi serves on the Diversity and Inclusion Advisory Council at BUSM, and is part of a leadership group engaging in health equity initiatives across the institution.

Presenter disclosures
Read more arrow_downward Hide arrow_upward

T. Neogi, Lilly, EMD Merck Serono, Novartis, Regeneron, Pfizer/Lilly


Feedback